Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the abuse potential of AZD7325.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Central Nervous System Depressants; Lorazepam

Criteria

Inclusion Criteria:

• Recreational CNS depressant use, defined as at least 10 lifetime occasions of non-medical use of drugs with depressant/sedative properties and at least 1 non-medical use in the year prior to screening

• Body mass index (BMI) within the range of 19.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at screening

• Willing and able to abide by all study requirements and restrictions

Exclusion Criteria:

• Unwillingness of inability to abstain from recreational drug use for the duration of the study from screening until follow-up

• Positive breath alcohol test prior to dosing

• Clinically significant abnormalities on physical examination, medical history, 12-lead ECG, vital signs, or safety laboratories